DSC Advisors’s Genocea Biosciences, Inc. GNCA Stock Holding History

DSC Advisors’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-4,617	Closed	-$54K	–	95
2017 Q3	$54K	Buy	+4,617	New	+$175K	0.02%	64

Other funds holding GNCA

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

DSC Advisors's GNCA Position: Q4 2017 in Review

DSC Advisors sold out of Genocea Biosciences, Inc. (GNCA) in Q4 2017, closing a stake of 4,617 shares — an estimated $54K sold.

DSC Advisors first reported a position in GNCA in Q3 2017 and held it in 1 quarter. The position peaked at $54K in Q3 2017. 56 funds tracked by Wall St. Rank hold GNCA as of Q4 2017.

DSC Advisors reported no remaining Genocea Biosciences, Inc. position as of Q4 2017 after selling out during the quarter.
DSC Advisors sold 4,617 Genocea Biosciences, Inc. shares in Q4 2017, an estimated $54K.
DSC Advisors first reported a position in Genocea Biosciences, Inc. in Q3 2017 and held it in 1 quarter.
DSC Advisors's Genocea Biosciences, Inc. position peaked at $54K in Q3 2017.
56 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q4 2017.

Based on DSC Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.